Khiron's Medical Clinics and Distribution Growth Throughout
Europe Follows Success in Latin American Marketplace
- Since establishing a Spanish subsidiary in 2019, Khiron's
scientific and medical team is recognized as cannabinoid experts in
Spain
- Khiron continues its long-standing relationship with the
Spanish Agency of Medicines and Medical Devices (AEMPS) and
actively contributes to several educational initiatives in
Spain
- Khiron provides comprehensive and certified medical education,
used worldwide to successfully educate thousands of prescribers and
created in close cooperation with renowned University Tecnologico
of Monterrey in Mexico
TORONTO, July 6, 2022
/CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company")
(TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical
cannabis throughout Europe and
Latin America, applauds recent
developments regarding the regulation of medical cannabis in
Spain. The company now looks
forward to bringing its clinical expertise and evidence from
Khiron-owned Zerenia™ Clinics in Colombia, Peru, Brazil,
and the UK to Spanish patients to guide medical
professionals for the benefit of Spanish patients.
Spain has been an important
exporter of medical cannabis in Europe, but Spain itself has not had national medical
cannabis legislation in place. With a population of more than 47
million people in Spain, experts
in the medical cannabis industry in Europe estimate that the potential market size
for the medical cannabis market is at least 700,000 patients or
1.5% of the country's total population.
Khiron has been active in Spain
since establishing its subsidiary Khiron Life Sciences Spain in
2019. For the past 3 years, Khiron has worked to
encourage this regulatory shift in Spain by promoting educational initiatives
together with a network of national collaborators such as the
Spanish Society for Research on Cannabinoids (SEIC), the
Iberoamerican Cannabinoid Research Network (CANNALATAN), Cannabmed
(ICEERS), the Cannabis Hub (Polytechnic University of Barcelona), the Sociedad Clínica de
Endocannabinología (SCE) and the Technological Agroalimentary
Center in Extremadura (CTAEX).
For Khiron, which already offers its cannabinoid-based medicines
and clinical services in two of the largest markets for medical
cannabis in Europe (Germany and the United Kingdom), it is a logical step
into Spain, one which the company
has been preparing for years. This process is further supported by
the steady expansion of Khiron Europe's medical portfolio, which
will grow with the recent acquisition of an EU GMP-certified German
pharmaceuticals manufacturer and wholesaler. The acquisition will
accelerate Khiron's growth in Europe by controlling the complete value chain
for its products and gaining direct access to European
pharmacies.
Franziska Katterbach, President of Khiron Europe, said: "We
welcome the planned regulation for medical cannabis in Spain. For Khiron, Spain is another important European market
with great potential in which we have been active since 2019 - but
the opening of the market for medical cannabis in Spain is even more important for the hundreds
of thousands of potential patients in Spain who do not have access to
cannabinoid-based therapies.
As a company, we look back on years of operational and physical
presence in Spain, with
participation in medical congresses, lectures at universities,
long-standing business relationships with national partners, and
cooperation with Spanish institutions. Khiron is well prepared for
the coming developments in Spain."
About Khiron Life Sciences Corp.
Khiron is a leading global medical cannabis company with core
operations in Latin America and
Europe. Leveraging wholly-owned
medical health clinics and proprietary telemedicine platforms,
Khiron combines a patient-oriented approach, physician education
programs, scientific expertise, product innovation, and a focus on
creating access to drive prescriptions and brand loyalty with
patients worldwide. The Company has a sales presence in
Colombia, Germany, the United
Kingdom, Peru, and
Brazil and is positioned to
commence sales in Mexico. The
Company is led by its co-founder and Chief Executive Officer,
Alvaro Torres, together with an
experienced and diverse executive team and board of directors.
Visit Khiron online at https://investors.khiron.ca
LinkedIn https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain "forward-looking information"
within the meaning of applicable securities legislation. All
information contained herein that is not historical in nature
constitutes forward-looking information. Forward-looking
information and statements contained herein reflect management's
current beliefs and is based on information currently available and
on assumptions that management believes to be reasonable. These
assumptions include, but are not limited to, assumptions regarding
the future regulatory developments and economic conditions, the
Company's ability to continue its growth and reduce costs. The
Company undertakes no obligation to update or revise any
forward-looking information, whether as a result of new
information, estimates or opinions, future events or results or
otherwise or to explain any material difference between subsequent
actual events and such forward-looking information, except as
required by applicable law.
View original
content:https://www.prnewswire.com/news-releases/medical-cannabis-leader-khiron-continues-global-expansion-into-spain-301581482.html
SOURCE Khiron Life Sciences Corp.